Back to CS Candriam S.C.A.

PTGXPTGX
13 quarters

Position history for CSCandriam S.C.A.'s holdings in PROTAGONIST THERAPEUTICS INC

No. Candriam S.C.A. exited its PTGX (Protagonist Therapeutics) position in Q4 2024. Its Q3 2024 13F listed 162,492 shares worth $7.3M. Candriam S.C.A. first reported PTGX in Q2 2021 and held it in 11 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$3.8M

Total Shares Change

-83,646

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2024-Q4
Latest
Exited
0
-100.0%
$00.0%$38.60
0
2024-Q3
Decreased
162,492
-40.7%
$7.3M0.0%$45.00
0
2024-Q2
Decreased
273,818
-23.9%
$9.5M0.1%$34.65
0
2024-Q1
Decreased
360,000
-33.0%
$10.4M0.1%$28.93
0
2023-Q4
Decreased
537,000
-14.8%
$12.3M0.1%$22.93
0
2023-Q3
Decreased
630,000
-13.1%
$10.5M0.1%$16.68
0
2023-Q2
Increased
725,000
+16.0%
$20M0.1%$27.62
39
2023-Q1
New
625,000
-
$13.2M0.1%$23.00
39
2022-Q2
Exited
0
-100.0%
$00.0%$7.91
0
2022-Q1
Unchanged
83,646
0.0%
$2M0.0%$23.68
0
2021-Q4
Unchanged
83,646
0.0%
$2.9M0.0%$34.20
0
2021-Q3
Unchanged
83,646
0.0%
$1.5M0.0%$17.72
0
2021-Q2
New
83,646
-
$3.8M0.0%$44.88
37

Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used